VYNDAMAX

This brand name is authorized in United States. It is also authorized in Hong Kong SAR China, Israel.

Active ingredients

The drug VYNDAMAX contains one active pharmaceutical ingredient (API):

1	Tafamidis UNII 8FG9H9D31J - TAFAMIDIS
	Tafamidis is a selective stabiliser of transthyretin (TTR). Tafamidis binds to TTR at the thyroxine binding sites, stabilising the tetramer and slowing dissociation into monomers, the rate-limiting step in the pathogenesis of transthyretin amyloidosis.
	Read more about Tafamidis

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VYNDAMAX Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N07XX08	Tafamidis	N Nervous system → N07 Other nervous system drugs → N07X Other nervous system drugs → N07XX Other nervous system drugs
Discover more medicines within N07XX08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
HK	Department of Health Drug Office	66860
IL	מִשְׂרַד הַבְּרִיאוּת	8550
US	FDA, National Drug Code	0069-8730